AI valuations are skyrocketing, but Guo, who also co-founded Scale AI thinks those valuations are reasonable, not a symptom ...
Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a trial designed to expand the label of the recently approved drug failed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback